22.3K subscribers
73.6K photos
35 videos
283 files
5.26K links
India's Fastest Stock Market News/Update Provider Telegram Channel

🔰For any query dm 👉 @ismdu

⛔️Disclaimer⛔️

All Posts Are For Educational Purposes. Do your own research before investing.
Download Telegram
#Cipla gets USFDA nod for Icatibant Injectable pre-Filled syringe.
#Cipla #Jubilant : To face action if they fail to fulfill supply obligation of Remdesivir within 24 hours: Karnataka govt
K'tka govt says Centre had directed Jubilant Ltd to supply 32,000 Remdesevir vials to the state by May9.
State has only received 17,601 vials frm co as May 8
CIPLA : #Cipla gets approval for #Novartis' Durezol generic version
#Cipla added to dow jones sustainability emerging markets index

#dow #markets #Cipla_Global
One of the core reasons for #Cipla's outperformance was its strategy and focus on the domestic market.
#Cipla Large Trade | 12.56 lakh shares (0.16% equity) worth ₹114.96 cr change hands at an avg ₹915/sh
#Cipla to report #Q4 results today, May 12. The street is expecting US sales to remain steady led by cancer drug Revlimid generic while sales could be around $185-214 m vs $195 m QoQ
#Cipla reports #Q4 results

Cons net profit at Rs 526 cr vs CNBC-TV18 poll of Rs 773.7 cr
#Cipla Q1 Results: North America sales highest ever in a quarter, profit, margin beat estimates
#Cipla up more than 7%, top Nifty gainer after co raises margin guidance to 23.5% from 23%
#Cipla shares jump over 8% on June quarter results
#Shares of #Cipla touched an all-time high of Rs 1,219 apiece, taking the m-cap close to Rs 1 lakh crore after the drugmaker delivered better-than-expected results in #Q1FY24.
Mint reports, #Cipla #Chairman calls reports w.r.t promoter stake sale, #speculative

All reports of stake sales by the promoters are speculative, the clarifications w.r.t promoter stake sale reports, are made to exchanges, From Mint: Cipla Chairman at AGM

Alert: Cipla held its… https://t.co/WJKocb7TI4 https://t.co/VL3OyfbSAl
#Cipla | Food & Drugs Administration (#FDA), Konkan Division, suspend FDA licence of company’s Patalganga manufacturing unit for 10 days in December 2023 for non-conformance of good #manufacturing practices https://t.co/yqVUWAqxGV
Torrent Pharma seen in race to buy promoter stake in #Cipla, may need investor support for stake buy. PEs like Blackstone, baring PE asia-EQT also likely in the fray: Sources to @ekta_batra

Alert: CNBC-TV18 reported Cipla promoters likely to sell stake to PEs

Here's more… https://t.co/Im8qpMeKz2 https://t.co/CFqcrLpCmG
#Cipla reports #Q4 earnings

➡️Revenue at ₹6,163 cr vs CNBC-TV18 poll of ₹6,250.9 cr
#Cipla confirms 2.53% stake sale by promoters
GST Council Likely To Give Relief On A Slew Of Cancer Drugs: Sources to TimsyJaipuria

📌Tax on Trastuzumab Deruxtecan, Osimertinib & Durvalumab can be cut to 5% from 12%
📌Fitment panel’s recommendations based on proposal shared by Health Ministry

📌Alert: Manufacturers of these #CancerDrugs are #Abbott, #ZydusLife, #Alkem, #RelianceLife, #Cipla, #Mylan & #Biocon
📌Alert: 54th #GSTCouncil to meet on September 9 in Delhi